Utility of Cell-Free DNA in the Clinic: Current State and Future Directions

AMP
9/28/21, 5:00 PM
America/New York GMT -4 summer

Description

This webinar will cover the evidence that circulating tumor DNA (ctDNA) minimal residual disease (MRD) can predict the development of cancer relapse in solid tumors and guide treatment personalization. In addition, it will discuss key issues for clinical implementation of ctDNA MRD testing, including the biology of ctDNA release, accounting for technical and biological background, determining the ideal timing of blood draws, and choosing a clinical assay.

 

Learning Objectives:

 

1. Identify challenges, and list possible solutions, unique to cfDNA assay validation.
2. Discuss opportunities for circulating tumor DNA assessment in oncology practices.
3. Discuss limitations of ctDNA assessment in oncology practices.

Previous registration necessary?

NO

YES
Simultaneous translation ?

NO

YES
Will it be recorded?
NO
YES

Lynette M. Sholl

Utility of Cell-Free DNA in the Clinic: Current State and Future Directions

Inglês

 

Speakers

Everett Moding

 

Link to the Event

Banner to the Event

Utility of Cell-Free DNA in the Clinic: Current State and Future Directions